Keyphrases
Adult Patients
33%
Anti-spike
20%
Antibody Deficiency
47%
Antibody Response
38%
Antireceptor
13%
B Cell Response
14%
Booster Vaccination
33%
Correlates of Protection
6%
COVID-19
83%
Cross-neutralization
5%
Delta Virus
6%
Fc Receptor Binding
6%
Gene Sequencing
33%
Healthy Donors
12%
Healthy Individuals
9%
Humoral Immune Response
6%
IgG1
33%
Immune Deficiency
11%
Immunization
6%
Immunodeficiency
33%
Immunoglobulin
22%
Immunoglobulin Prophylaxis
11%
Immunoglobulin Replacement
53%
Immunoglobulin Replacement Therapy (IgRT)
6%
Memory B Cells
9%
Memory B-cell Response
33%
MRNA Vaccine
33%
Neutralizing Activity
46%
Neutralizing Antibodies
6%
Omicron Variant
38%
Passive Immunity
5%
Poor Response
5%
Primary Antibody Deficiency
66%
Primary Vaccination
14%
Protective Behavior
12%
Receptor Binding Activity
6%
Receptor-binding Domain
13%
Replacement Product
53%
Response to Vaccination
5%
SARS-CoV-2 Infection
33%
SARS-CoV-2 Vaccine
9%
Serum Neutralizing Antibodies
6%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
6%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
6%
Severe Acute Respiratory Syndrome coronavirus-2 Vaccine
6%
Sustained Response
6%
T Cell Response
9%
Titer
13%
Virus
6%
XBB.1.5
11%
Immunology and Microbiology
Antibody Response
38%
Antibody Titer
9%
B Cell
14%
COVID-19
18%
Fc Receptor
5%
Gene Sequence
33%
Hepatitis Delta Virus
5%
Humoral Immune Deficiency
66%
Humoral Immunity
5%
Immune Response
9%
Immunodeficiency
42%
Immunodeficiency
7%
Immunoglobulin G1
33%
Intravenous Immunoglobulin
55%
Memory B Cell
33%
Neutralizing Antibody
5%
Omicron Coronavirus Variant
41%
Receptor Binding
16%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Spike
20%
T Cell
9%
Titer
11%
Medicine and Dentistry
B Cell
14%
COVID-19 Vaccine
9%
Humoral Immune Deficiency
33%
Immune Response
9%
Immunoglobulin G1
33%
Memory B Cell
33%
Messenger RNA
9%
Severe Acute Respiratory Syndrome Coronavirus 2
33%
T-Cell Response
14%
